You are viewing: Japan Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Japan Nuclear Medicine Market was valued at $694.8 Million in 2025 and projected to reach to $1484.4 Million by 2030, representing a compound annual growth rate of 16.4%. Japan's nuclear medicine market is poised for substantial growth through 2030, driven by demographic shifts and disease burden.

Japan Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Nuclear Medicine Market Trends and Insights

  • Japan's aging population and rising prevalence of cancer and cardiovascular diseases are driving demand for diagnostic and therapeutic nuclear medicine procedures.
  • Japan's advanced healthcare infrastructure and high adoption of cutting-edge imaging technologies position the country as a key growth market in the Asia Pacific region. The Japanese nuclear medicine sector benefits from strong government support for healthcare innovation and significant investment in medical imaging facilities.
  • Japan's emphasis on early disease detection and personalized medicine is accelerating the uptake of PET-CT and SPECT imaging modalities.
  • Between 2025 and 2030, Japan is expected to witness increased clinical applications of radiopharmaceuticals and expansion of nuclear medicine centers across urban and regional healthcare networks..

Key Market Statistics

  • CAGR (2025-2030) 16.4% CAGR
  • Market Size, 2025 ~USD 694.8 Million
  • Forecast, 2030 ~USD 1484.4 Million
  • Country Japan

Japan Nuclear Medicine Market Overview

Aging Population Catalyst :

Japan's rapidly aging demographic, with over 29% of the population aged 65+, is significantly driving demand for nuclear medicine diagnostics and therapeutics, particularly for cancer and cardiovascular disease management.

Advanced Healthcare Infrastructure :

Japan's world-class healthcare system and high adoption rate of cutting-edge imaging technologies position it as a leader in nuclear medicine innovation and procedure utilization in Asia.

Strong Market Growth :

With a CAGR of 16.4% from 2025 to 2030, Japan's nuclear medicine market is expanding faster than the global average of 15.1%, reflecting increasing clinical adoption and investment.

Disease Prevalence Drivers :

Rising incidence of cancer and cardiovascular diseases in Japan is accelerating demand for PET/CT scans, SPECT imaging, and targeted radiotherapy treatments across major metropolitan healthcare centers.

Japan Nuclear Medicine Market Dynamics

  • The country's commitment to healthcare excellence and technological advancement ensures continued investment in nuclear imaging and therapeutic capabilities.
  • Regulatory support and reimbursement policies favor nuclear medicine adoption, while collaborations between Japanese hospitals and international vendors strengthen market expansion.
  • The market will likely see increased demand for personalized medicine approaches and hybrid imaging technologies tailored to Japan's healthcare needs..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Japan's nuclear medicine market is valued at USD 694.8 million in 2025 and will grow to USD 1,484.4 million by 2030, representing a 16.4% CAGR.
    • Japan's aging demographic and high cancer incidence rates are primary drivers of nuclear medicine demand across diagnostic and therapeutic applications.
    • Japan's advanced healthcare infrastructure and government support for medical innovation accelerate adoption of PET-CT and SPECT imaging technologies.
    • Japan is positioned as a leading Asia Pacific market for nuclear medicine, with expanding clinical applications and growing radiopharmaceutical utilization through 2030.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    Japan Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES5057.866.877.389.4103.4119.5137.915.6
    DIAGNOSTIC & IMAGING CENTERS140.2164.8193.9228.2268.5315.7371.1435.517.6
    HOSPITALS304.9354411.2477.7554.8644747865.316
    OTHER END USERS17.219.822.826.230.234.739.945.815
    TOTAL512.2596.4694.8809.5942.91097.81277.41484.416.4

    Target Audience

    • Medical Device Manufacturers : Need Japan-specific market data to develop localized product strategies, understand reimbursement pathways, and identify opportunities for PET/CT, SPECT, and radiotherapy equipment sales in this high-growth market.
    • Pharmaceutical & Radiopharmaceutical Companies : Require detailed insights into Japan's nuclear medicine procedures and disease prevalence to guide R&D investments, clinical trial planning, and commercialization strategies for diagnostic and therapeutic radiopharmaceuticals.
    • Healthcare Investors & Private Equity : Seek validated market sizing and growth projections for Japan to evaluate investment opportunities in nuclear medicine facilities, imaging centers, and healthcare technology companies operating in this expanding sector.
    • Hospital & Diagnostic Center Operators : Need market intelligence on Japan's nuclear medicine demand, competitive landscape, and technology trends to optimize service offerings, capital expenditure planning, and operational efficiency in imaging departments.
    • Market Research & Consulting Firms : Require Japan-specific nuclear medicine market data and forecasts to support client advisory services, competitive analysis, and strategic recommendations for healthcare stakeholders across the value chain.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for Japan's nuclear medicine market (USD 694.8M in 2025) with verified 16.4% CAGR projections through 2030, enabling accurate financial forecasting and investment decisions.
    • Japan-Specific Competitive Intelligence : Gain detailed insights into Japan's unique market dynamics, regulatory environment, and competitive landscape to develop targeted market entry or expansion strategies specific to Japanese healthcare providers.
    • Demographic & Clinical Opportunity Analysis : Understand Japan's aging population impact and disease prevalence trends driving nuclear medicine demand, allowing stakeholders to align product development and marketing with actual clinical needs.
    • Regional Performance Benchmarking : Compare Japan's 16.4% CAGR against global 15.1% average to assess relative market attractiveness and identify Japan as a priority market for resource allocation and partnership development.
    • Strategic Planning & Risk Mitigation : Access comprehensive Japan market forecasts through 2030 to support long-term strategic planning, capital allocation, and risk assessment for healthcare technology and pharmaceutical investments.

    Frequently asked questions

    What is the current size of Japan's nuclear medicine market?

    Japan's nuclear medicine market is valued at USD 694.8 million in 2025 and is projected to reach USD 1,484.4 million by 2030.

    What is the expected growth rate for Japan's nuclear medicine market?

    Japan's nuclear medicine market is expected to grow at a compound annual growth rate (CAGR) of 16.4% from 2025 to 2030.

    What factors are driving growth in Japan's nuclear medicine market?

    Key drivers include Japan's aging population, rising cancer and cardiovascular disease prevalence, advanced healthcare infrastructure, government support for medical innovation, and increased adoption of PET-CT and SPECT imaging technologies.

    Which imaging modalities are most prevalent in Japan's nuclear medicine sector?

    PET-CT and SPECT imaging modalities are the most widely adopted in Japan, supported by strong healthcare infrastructure and clinical emphasis on early disease detection.

    How does Japan's nuclear medicine market compare to other Asia Pacific countries?

    Japan is positioned as a leading Asia Pacific market for nuclear medicine due to its advanced healthcare system, high healthcare spending, aging population, and strong government support for medical innovation.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status